Whitehawk Therapeutics (WHWK) Capital Expenditures (2016 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Capital Expenditures of -$552000.0 for Q3 2025, up 66.48% year-over-year from -$331562.4 in Q3 2024, and down 182.88% quarter-over-quarter from $666000.0 in Q2 2025.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) Capital Expenditures (2016 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Capital Expenditures for 10 consecutive years, with -$552000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Capital Expenditures rose 66.48% year-over-year to -$552000.0; the TTM figure through Mar 2026 stood at $114000.0 (down 93.21% YoY), while the FY2024 annual figure was $1.7 million, up 419.31% from the prior year.
- Capital Expenditures declined to -$552000.0 in Q3 2025 per WHWK's latest filing, from $666000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.0 million in Q4 2024 and bottomed at -$1.6 million in Q3 2024.
- Historically, Capital Expenditures has averaged $68687.5 across 5 years, with a median of -$45500.0 in 2022.
- Annual changes were most pronounced in 2021 — Capital Expenditures tumbled 758.55% — and 2024, when it soared 1784.17%.
- Whitehawk Therapeutics' Capital Expenditures stood at -$481000.0 in 2021, then surged by 179.83% to $384000.0 in 2022, then plunged by 131.25% to -$120000.0 in 2023, then jumped by 1784.17% to $2.0 million in 2024, then slumped by 127.31% to -$552000.0 in 2025.
- Business Quant data shows WHWK's Capital Expenditures at -$552000.0 in Q3 2025, $666000.0 in Q2 2025, and -$114000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | -162,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -162,000.00 |
| Mar 31, 2026 | -163,000.00 |
| Dec 31, 2025 | -49,000.00 |
| Sep 30, 2025 | -165,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Dec 31, 2024 | 186,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 541,000.00 |
| Mar 31, 2024 | 739,000.00 |
| Dec 31, 2023 | 816,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 689,000.00 |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 650,000.00 |
| Jun 30, 2022 | -159,000.00 |
| Mar 31, 2022 | -125,000.00 |
| Dec 31, 2021 | -51,000.00 |
| Sep 30, 2021 | -430,000.00 |